Quratis Inc is a Korea-based company primarily engaged in the manufacture and sale of biopharmaceuticals. The Company is engaged in the manufacture and sale of vaccine, peptide nucleic acid complex. The Company is also engaged in the provision of Cell Penetrating Peptide (CPP) platform services. In addition, the Company is engaged in the development and research of vaccines, such as tuberculosis vaccines for adults and adolescents, and COVID-19 vaccines.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-23	₩4,105.00	+7.60%	164,898
26-09-22	₩3,815.00	-13.30%	241,697
26-09-21	₩4,400.00	-3.08%	1,785,121
26-09-18	₩4,540.00	-5.71%	2,552,429

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-09-23			5-day change	1st Jan Change
4,105.00 ^KRW	+7.60%		-9.58%	-64.91%

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI

Market Cap	48.15B 35.47M 31.12M 29.39M 26.79M 50.15M 3.4B 50.5M 352M 136M 1.74B 133M 130M 5.58B	P/E 2024	-9.06x	P/E 2025	-28.4x
Enterprise Value	48.3B 35.58M 31.22M 29.49M 26.87M 50.3M 3.41B 50.66M 353M 137M 1.74B 134M 131M 5.6B	EV / Sales 2024	136x	EV / Sales 2025	43.3x
Free-Float	37.62%	Yield 2024 *	-	Yield 2025	-

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
02-25	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
12-23	Quratis wins contract amount of 1 billion won	RE
25-08-21	Access to Advanced Health Institute Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines	CI
25-06-19	Quratis To Invest 7 Billion Won In New Facility	RE
25-03-11	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
25-02-20	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI
24-11-24	Quratis Inc. announced that it expects to receive KRW 6.4993 billion in funding from Inventage Lab, Inc.	CI
24-11-14	Quratis Inc. announced that it has received KRW 10.4648 billion in funding from LINFRA Corp	CI
24-09-11	Quratis Inc. announced that it expects to receive KRW 10.4648 billion in funding from LINFRA Corp	CI
23-11-29	Quratis Inc. announced that it has received KRW 7.99999791 billion in funding from LINFRA Corp	CI
23-09-24	Quratis Inc. announced that it expects to receive KRW 7.99999791 billion in funding	CI

1 day	+7.60%
1 week	-9.58%
Current month	+49.27%
1 month	+48.73%
3 months	+38.22%
6 months	-54.39%
Current year	-64.91%

Quratis Inc. Stock

Stocks

A348080

KR7348080003

Pharmaceuticals

Valuation: Quratis Inc.

Chart: Quratis Inc.

Latest news: Quratis Inc.

Press Releases: Quratis Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Quratis Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	3,770	5,400
1 month	2,605	6,140
Current year	1,765	13,050
1 year	1,765	13,365
3 years	1,765	36,270
5 years	1,765	60,210
10 years	1,765	60,210

Manager	Title	Age	Since
Seong Kim CEO	Chief Executive Officer	52	2024-12-15
Chi-Yeol Kim AUD	Comptroller/Controller/Auditor	48	2025-04-06

Director	Title	Age	Since
Dong-Hun Kim CHM	Chairman	56	2025-02-19
Hyeong-Gi Choi BRD	Director/Board Member	39	2025-02-19
Taek-Dong Kim BRD	Director/Board Member	63	2025-02-19

Date	Insider	Type	Quantity	% Market Cap.
5/7/25	Ki-Young Yang	Others	80,000	0.1380%
5/9/24	Woo Ryu Sung	Others	41,946	0.0995%
4/2/24	Sang-Rae Cho	Others	118,333	0.2807%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
QURATIS INC.	+7.60%	-9.58%	-51.79%	-83.53%	35.47M
ELI LILLY AND COMPANY	+0.13%	+2.65%	+63.34%	+115.17%	1,055B
JOHNSON & JOHNSON	+0.20%	+0.46%	+50.92%	+70.56%	654B
ABBVIE INC.	-0.29%	+0.14%	+19.82%	+71.75%	467B
ROCHE HOLDING AG	-0.85%	+0.98%	+42.13%	+44.64%	348B
NOVARTIS AG	+0.71%	+4.08%	+21.75%	+28.83%	275B
ASTRAZENECA PLC	+1.23%	+0.42%	+14.11%	+12.43%	258B
AMGEN INC.	+2.11%	+7.51%	+51.88%	+54.11%	224B
GILEAD SCIENCES, INC.	+0.83%	+0.55%	+34.64%	+99.83%	187B
NOVO NORDISK A/S	0.00%	-10.14%	-27.40%	-61.08%	171B
Average	+1.17%	-0.81%	+21.94%	+35.27%	363.84B
Weighted average by Cap.	+0.27%	+1.32%	+40.42%	+68.21%

	2024	2025
Net sales	374M 275K 242K 228K 208K 389K 26.39M 392K 2.73M 1.06M 13.48M 1.03M 1.01M 43.33M	2.46B 1.81M 1.59M 1.5M 1.37M 2.56M 173M 2.58M 17.95M 6.95M 88.62M 6.8M 6.65M 285M
Net income	-26.27B -19.35M -16.98M -16.04M -14.61M -27.36M -1.85B -27.55M -192M -74.33M -947M -72.65M -71.08M -3.05B	-29.67B -21.86M -19.18M -18.12M -16.51M -30.9M -2.1B -31.13M -217M -83.97M -1.07B -82.07M -80.3M -3.44B
Net Debt	16.3B 12.01M 10.54M 9.95M 9.07M 16.98M 1.15B 17.1M 119M 46.12M 588M 45.08M 44.11M 1.89B	149M 110K 96.38K 91.02K 82.95K 155K 10.53M 156K 1.09M 422K 5.38M 412K 403K 17.28M